Distalmotion raises USD 150M to accelerate FDA approval and clinical experience of its robotic platform Dexter

20.04.2023 09:31, Guillaume Tinsel

Distalmotion announced today the first closing of its USD 150 million financing. This significant fundraising reinforces the confidence of its existing investors led by Revival Healthcare Capital. Dexter, Distalmotion’s robotic platform, is in daily clinical use in Europe, successfully treating patients across many complex and high-volume general surgery, gynecology, and urology procedures. This funding will enable US Food and Drug Administration (FDA) approval and to continue accelerating clinical experience in Europe.

“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive patient care,” explained Distalmotion CEO Michael Friedrich. “Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments. Surgeons are therefore empowered with choice and control."
  Dexter makes robotic surgery more accessible, enabling wider adoption of robotic surgery. Dexter is easily integrated into clinical practice – it requires no additional infrastructure, it fits into every clinical setting, and it is mobile allowing for easy sharing across departments. This empowers institutions to scale robotics programs across surgical disciplines to offer more patients an enhanced standard of care in both hospital and surgery center settings.
“Dexter delivers what surgeons need most when it matters most. It provides advanced dexterity for complex surgical steps such as suturing, dissection, and working in confined spaces” said Prof. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital who performed the first general surgery procedure with Dexter in 2021. “Dexter's open platform allows surgeons to choose the best-in-class tools and technology for each procedure step. It is compatible with all 3D laparoscopes which allow surgeons to leverage current and future imaging innovations.”

“This latest financing sets the stage for Distalmotion to accelerate our mission of expanding the adoption of Dexter to hospitals worldwide,” said Rick Anderson, Chairman of Revival and Chairman of Distalmotion. “We are very proud of our global leadership team’s accomplishment to bring Distalmotion’s technology to the market and to set the stage for the company’s entry into the US market”.

Distalmotion won Venture Kick in 2012, participated in Venture Leaders Technology in 2011, and Venture Leaders China in 2018, and was among the TOP 100 Swiss startups from 2013 to 2017.